| Price | 2,144.00p on 03-04-2026 at 04:45:12 |
|---|---|
| Change | 0.00p 0% |
| Buy | 2,143.00p |
| Sell | 2,141.00p |
| Last Trade: | Sell 57,055.00 at 2,144.00p |
| Day's Volume: | 0 |
| Last Close: | 2,144.00p |
| Open: | 0.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 1,242.50p - 2,282.00p |
| Market Capitalisation: | £85.69b |
| VWAP: | 0.00p |
| Shares in Issue: | 4.00b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 57,055 | 2,144.00p | SI Trade Suspected SELL Trade |
17:20:25 - 02-Apr-26 |
| Sell* | 1,756 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:59 - 02-Apr-26 |
| Sell* | 5,677 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:59 - 02-Apr-26 |
| Sell* | 1,885 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:59 - 02-Apr-26 |
| Sell* | 2,720 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:59 - 02-Apr-26 |
| Sell* | 185,605 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:59 - 02-Apr-26 |
| Sell* | 12,740 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:58 - 02-Apr-26 |
| Sell* | 5,510 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:58 - 02-Apr-26 |
| Sell* | 1,429 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:58 - 02-Apr-26 |
| Sell* | 245 | 2,144.00p | SI Trade Suspected SELL Trade |
17:19:58 - 02-Apr-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 2nd Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 1st Apr 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 1st Apr 2026 3:00 pm | RNS | Total Voting Rights |
| 1st Apr 2026 7:00 am | RNS | ViiV completes changes to minority shareholding |
| 1st Apr 2026 7:00 am | RNS | Transaction in Own Shares |
| 31st Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 30th Mar 2026 7:05 am | RNS | Bepirovirsen accepted for review in China |
| 30th Mar 2026 7:00 am | RNS | Exdensur approved for severe asthma in China |
| 30th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 27th Mar 2026 7:00 am | RNS | Bepirovirsen accepted for review by the EMA |